ARDS (Aridis Pharmaceuticals) Stock Based Compensation: $0.97 Mil (TTM As of Sep. 2023)


ARDS Aridis Pharmaceuticals Inc ARDS
12 GF Score
Price $0.00
View Full Analysis

What is Aridis Pharmaceuticals Stock Based Compensation?

Aridis Pharmaceuticals ARDS -99.00% 12 Stock Based Compensation is $0.97 Mil as of Sep. 2023. GuruFocus rates ARDS with a GF Score™ of 12/100.

Aridis Pharmaceuticals's Stock Based Compensation for the three months ended in Sep. 2023 was $0.20 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2023 was $0.97 Mil.

Aridis Pharmaceuticals Stock Based Compensation Related Terms

Aridis Pharmaceuticals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Aridis Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aridis Pharmaceuticals Stock Based Compensation Chart

Aridis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Stock Based Compensation
Get a 7-Day Free Trial 1.66 2.01 2.13 2.25 1.48

Aridis Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.32 0.25 0.21 0.20
ARDS
12GF Score
Aridis Pharmaceuticals Inc ARDS
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aridis Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.97 Mil.

What does a Stock Based Compensation of $0.97 Mil mean?
Aridis Pharmaceuticals (ARDS) has a Stock Based Compensation of $0.97 Mil as of Sep. 2023. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Aridis Pharmaceuticals and its competitors.
Is Aridis Pharmaceuticals' Stock Based Compensation too high?
Aridis Pharmaceuticals' current Stock Based Compensation is $0.97 Mil. Overall, Aridis Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aridis Pharmaceuticals' Stock Based Compensation compare to ARTL and REVB?
Aridis Pharmaceuticals' Stock Based Compensation of $0.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Aridis Pharmaceuticals and its competitors. Aridis Pharmaceuticals's current Stock Based Compensation is $0.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aridis Pharmaceuticals stock overvalued right now?
Aridis Pharmaceuticals (ARDS) has a current Stock Based Compensation of $0.97 Mil. The current Stock Based Compensation is $0.97 Mil. Aridis Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Aridis Pharmaceuticals (ARDS), the current Stock Based Compensation is $0.97 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aridis Pharmaceuticals Business Description

Address 983 University Avenue, Building B, Los Gatos, CA, USA, 95032
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
12GF Score

Get the complete analysis for ARDS

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price